Positive Phase III results for Lynparza plus abiraterone in metastatic prostate cancer
Positive high-level results from the PROpel Phase III trial have shown that AstraZeneca and MSD’s Lynparza (olaparib), in combination with abiraterone, dem...
Continue Reading →
